DelveInsight’s Sepsis market report offers comprehensive coverage of the current treatment practices, pipeline therapies, and market share of the individual drug, current and forecasted Sepsis market size from 2018 to 2030 in the 7MM.
Some of the Crucial Highlights from the Sepsis Market Report
As per DelveInsight estimates, the total Sepsis incidence was over 3 million in the 7MM in 2020, with the US accounting for the maximum Sepsis incidence.
Among the EU5 countries, Germany had the highest Sepsis incident cases while France accounted for the least Sepsis incident cases in 2020.
According to DelveInsight Sepsis epidemiology analysis, males are more affected as compared to females.
Leading players such as Shionogi, Inotrem, Asahi Kasei Pharma Corp., Adrenomed, AM-Pharma, Revimmune, among others, are diligently working to improve the Sepsis treatment landscape.
Key Sepsis therapies in the pipeline include Fetroja/Fetcroja, Nangibotide, Recomodulin, Adrecizumab, Endogenous enzyme alkaline phosphatase, CYT107, and others.
CYT107 (Revimmune) could be a game-changer in treating sepsis patients, as it restores adaptive immunity.
The Sepsis market size was found to be USD 2,458 million in the 7MM in 2020.
For further information on the disease, request for the sample @ Sepsis Treatment Guidelines
Sepsis Overview
Sepsis is a life-threatening organ failure induced by a faulty infection response. Sepsis is a clinical manifestation of infections that can be acquired in both the community and healthcare institutions. Sepsis can develop in anyone who has had an infection, a traumatic injury, or a serious non-communicable disease.
Sepsis Epidemiology Segmentation
The Sepsis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Sepsis Total Incident Cases
Sepsis Gender-Specific Incident Cases
Sepsis Severity-Specific Incident Cases
Sepsis Origin-Specific Incident Cases
Sepsis Therapeutics Market
The main option for Sepsis treatment is antibiotics, vasoactive medications, insulin, and painkillers. In severe Sepsis cases, extracorporeal therapies are also used. The most commonly used antibiotics for Sepsis treatment include ceftriaxone (off-label), meropenem (Merrem), ceftazidime (Fortaz), cefotaxime (Claforan), cefepime (Maxipime), piperacillin and tazobactam (Zosyn), ampicillin and sulbactam (Unasyn), imipenem/cilastatin (Primaxin), levofloxacin (Levaquin), and clindamycin (Cleocin). In addition, Oritavancin, dalbavancin, and tedizolid are among the FDA- approved antibiotics for Sepsis.
Apart from these, there are some marketed Sepsis therapies also such as GIAPREZA (angiotensin II), Vasostrict (vasopressin), Empressin (Argipressin), and Recomodulin (ART-123).
Sepsis Market Outlook
The Sepsis market is expected to witness the launch of upcoming therapies by key pharmaceutical companies, including Shionogi, Inotrem, Asahi Kasei Pharma Corp., Adrenomed, and several others.
Get a detailed analysis of the market @ Sepsis Market Size
Sepsis Pipeline Therapies and Key Companies
Fetroja/Fetcroja: Shionogi
Nangibotide: Inotrem
Recomodulin: Asahi Kasei Pharma Corp.
Adrecizumab: Adrenomed
Endogenous enzyme alkaline phosphatase: AM-Pharma
CYT107: Revimmune
Sepsis Market Drivers
Rising Sepsis Incidence
Innovations in R&D strategies
Increasing awareness
Expected approval of pipeline drugs in the forecasted period
Understanding of Sepsis pathophysiology
Sepsis Market Barriers
Lack of a gold standard test causes a delay in diagnosis.
The disease burden associated with the high cost of treatment
Limitations related to defining Sepsis
Trial Failures and Drug withdrawal from the market
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Sepsis Key Companies: Shionogi, Inotrem, Asahi Kasei Pharma Corp., Adrenomed, AM-Pharma, Revimmune, among others.
Sepsis Key Pipeline Therapies: Fetroja/Fetcroja, Nangibotide, Recomodulin, Adrecizumab, Endogenous enzyme alkaline phosphatase, CYT107, and others.
Sepsis Segmentation: By Geography, By Sepsis therapies
Analysis: Comparative and conjoint analysis of Sepsis emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Sepsis Market Overview at a Glance
4.
Executive Summary of Sepsis
5.
Sepsis Disease Background and Overview
6.
Sepsis Epidemiology and Patient Population
7.
Patient Journey
8.
Organizations contributing towards Sepsis
9.
Sepsis Marketed Therapies
10.
Sepsis Emerging Therapies
11.
Sepsis: Seven Major Market Analysis
12.
Sepsis Seven Major Market Outlook
13.
KOL Views
14.
15.
16.
SWOT Analysis
17.
Sepsis Unmet Needs
18.
Sepsis Reimbursement and Market Access
19.
Appendix
20.
DelveInsight Capabilities
21.
Disclaimer
22.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Related Reports
Septic Shock Market
Get a comprehensive analysis of Septic Shock pipeline therapies and key companies such as Adrenomed AG, Vivacelle Bio, Inotrem, Atox Bio, AM-Pharma, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/